MedPath

Johnson & Johnson

Johnson & Johnson logo
🇺🇸United States
Ownership
Public
Established
1886-01-01
Employees
131.9K
Market Cap
$392.2B
Website
http://www.jnj.com
Introduction

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

janssen.com
·

Lung Cancer | Janssen

Johnson & Johnson Oncology collaborates with experts to innovate in oncology, aiming for better patient outcomes. Their Lung Cancer Initiative focuses on improving lung cancer care globally, with expansion into the EMEA region to enhance screening, prevention, and interception efforts.
biospace.com
·

Recursion Provides Business Updates and Reports First Quarter 2024 Results

Recursion reported Q1 2024 updates, including Phase 2 clinical trials progress, BioHive-2 supercomputer benchmarking, and a Helix partnership for AI model training. They also announced financial results, with a net loss of $91.4M, and plans for future trials and collaborations.
jdsupra.com
·

Alvotech and Teva’s Selarsdi™ (ustekinumab-aekn), Biosimilar to Stelara® Approved by FDA

Alvotech and Teva's Selarsdi™, a biosimilar to Stelara®, was FDA approved on April 16, 2024, with a U.S. market entry by February 21, 2025. This marks the second Stelara® biosimilar approval, following Amgen's Wezlana™. Four other Stelara® biosimilars are pending approval. Stelara®'s 2023 U.S. sales were ~$6.97B.
goodwinlaw.com
·

FDA Approval of Alvotech/Teva Ustekinumab Biosimilar

Alvotech and Teva announced FDA approval of SELARSDI, a biosimilar to Johnson & Johnson’s STELERA®, for treating moderate to severe plaque psoriasis and psoriatic arthritis. SELARSDI, developed by Alvotech and commercialized by Teva, is the second ustekinumab biosimilar approved by the FDA, following Amgen’s WEZLANA.
goodwinlaw.com
·

FDA Approves BMS and J&J CAR-T Cell Therapies for Earlier Treatment of Multiple Myeloma

FDA approved ABECMA for earlier treatment of relapsed/refractory multiple myeloma after two prior therapies, expanding its use beyond four lines. Similarly, CARVYKTI received FDA approval for patients after one prior therapy, marking it as the first BCMA-targeted therapy for early relapse treatment.
aabb.org
·

FDA Expands CAR T Approvals for Patients With Multiple Myeloma

FDA approved expanded use of CAR T-cell therapies, ide-cel and cilta-cel, for earlier treatment of relapsed or refractory multiple myeloma. Ide-cel now treats after two prior therapies, showing a 51% risk reduction in disease progression. Cilta-cel is approved for patients after one prior therapy, reducing risk by 59%. Both have known safety profiles.
onclive.com
·

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Therapy

FDA approved ciltacabtagene autoleucel (Carvykti) for relapsed/refractory multiple myeloma patients, based on CARTITUDE-4 study showing 59% reduced risk of disease progression or death. Median PFS not reached with cilta-cel vs 11.8 months with standard care. Cilta-cel showed 75.9% 12-month PFS rate, 73.1% CR or better rate, and 84.6% ORR. Safety profile includes grade 3/4 toxicities and boxed warnings for CRS, ICANS, and secondary malignancies.
prnewswire.com
·

CARVYKTI® is the First and Only BCMA-Targeted Therapy for Early Relapse in Multiple Myeloma

FDA approved CARVYKTI® for treating relapsed/refractory multiple myeloma, reducing disease progression or death risk by 59% vs standard therapies. Based on Phase 3 CARTITUDE-4 study, it's the first BCMA-targeted therapy for early relapse, offering a potential treatment-free period.
medcitynews.com
·

Startup Orbis Medicines Launches With €26M for Next-Generation Peptide Drugs

Orbis Medicines, backed by €26M, aims to develop orally dosed peptide-based drugs using macrocycles for better bioavailability and cellular permeability. Their technology enables rapid synthesis and screening of compounds, targeting validated antibody drug targets for more convenient patient treatment.

Patient centricity, AI and ML, new technologies in clinical trials

The SCOPE Summit 2024 emphasized patient-centered clinical trials, discussing AI, ML, sustainability, and inclusivity. Key topics included integrating trials into care, LGBTQ+ inclusivity, rare pediatric trials, and AI's role in protocol development. Sustainability efforts and advancements in digital markers for diseases like Alzheimer's were also highlighted.
© Copyright 2025. All Rights Reserved by MedPath